IL-16 variability and modulation by antiallergic drugs in a murine experimental allergic rhinitis model.
BACKGROUND
Interleukin-16 (IL-16) is a cytokine that induces selective migration of CD4+ cells and participates in inflammatory diseases including allergic rhinitis. Histamine and prostaglandin D(2) are important chemical mediators of allergic inflammation, and antiallergic drugs are commonly used for the treatment of allergic rhinitis. It remains unknown whether treatment with the drugs affects IL-16.


OBJECTIVE
We evaluated the variability of IL-16 and the effects of the antiallergic drugs fexofenadine (40 mg/kg/day) and ramatroban (30 mg/kg/day) on IL-16 in an OVA-sensitized BALB/c murine experimental allergic rhinitis model.


METHODS
We measured the expression level of IL-16 protein in the mouse nasal septal mucosa by immunohistochemistry, and the serum level of IL-16 by ELISA. Several other parameters associated with allergic rhinitis (nasal symptoms, OVA-specific IgE, eosinophil and T cell infiltration) were also measured.


RESULTS
Local and systemic expressions of IL-16 were significantly increased in OVA-sensitized mice when compared to the nonsensitized group. Fexofenadine and ramatroban significantly inhibited the following OVA-induced allergic features when compared to the nontreated sensitized group: sneezing, nasal rubbing, eosinophil infiltration, IL-16 expressions in nasal tissue, and serum IL-16 level. Serum OVA-specific IgE and local T cell infiltration were reduced, but they did not reach significant values.


CONCLUSIONS
These results suggest that IL-16 was both systemically and locally upregulated in the murine allergic rhinitis model and that IL-16 changed in parallel to allergic state by treatment with the drugs.
Akiyama
Kosuke
K
Department of Otorhinolaryngology, Faculty of Medicine, Kagawa University, Kagawa 761-0793, Japan. kakaka@med.kagawa-u.ac.jp
Karaki
Masayuki
M
Kobayshi
Ryuichi
R
Dobashi
Hiroaki
H
Ishida
Toshihiko
T
Mori
Nozomu
N
D000818:Animals; D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D002227:Carbazoles / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004804:Eosinophils / Q000187:drug effects / Q000276:immunology* / Q000378:metabolism; D005260:Female; D007073:Immunoglobulin E / Q000097:blood; D019410:Interleukin-16 / Q000096:biosynthesis* / Q000097:blood / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D009297:Nasal Mucosa / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D010047:Ovalbumin / Q000276:immunology; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy / Q000276:immunology*; D013449:Sulfonamides / Q000627:therapeutic use*; D016593:Terfenadine / Q000031:analogs & derivatives* / Q000627:therapeutic use
D018926:Anti-Allergic Agents; D002227:Carbazoles; D019410:Interleukin-16; D010975:Platelet Aggregation Inhibitors; D013449:Sulfonamides; D007073:Immunoglobulin E; D016593:Terfenadine; D010047:Ovalbumin; C093230:fexofenadine; C063119:ramatroban